Sanofi reports positive results for potential mRNA COVID-19 shot
The Peninsula
PARIS: Sanofi on Tuesday announced positive interim results from its early-stage study for the mRNA-based COVID-19 vaccine candidate it is developing with Translate Bio, a boost for the French drug company after delays with its other shot.
Sanofi said initial data Phase I/II from these results showed neutralising antibody seroconversion in 91%-100% of study participants, two weeks after a second injection, across all three dosages tested.
"These results will clearly help inform the path forward for our mRNA development programs," said Jean-Francois Toussaint, global head of research and development at Sanofi Pasteur.
More Related News